Talotrexin

DB06178InvestigationalSmall molecule

Investigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid).

Chemical structure of Talotrexin
Primary indication
Investigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid).Curator reviewed
Formula / weight
C27H27N9O6 · 573.56 g/mol (avg)
Code names
NSC-623017

Resolves to

Compound
UNIIA8E516A20KCAS113857-87-7ChEMBLCHEMBL590985
Structure
InChIKeyNYQPLPNEESYGNO-IBGZPJMESA-NSMILESNC1=NC(N)=C2N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCCNC(=O)C3=CC=CC=C3C(O)=O)C(O)=O)C=NC2=N1
Targets
P15328FOLR1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Talotrexin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In